ReviewPituitary2017
How effective is temozolomide for treating pituitary tumours and when should it be used?
Review in Pituitary, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.
- Treatment of non-functioning pituitary adenoma with cabergoline: a systematic review and meta-analysis.Pituitary · 2022Pooled it
- Heterogeneity of MGMT expression in corticotroph adenomas and mechanism of acquired temozolomide resistance.The Journal of clinical endocrinology and metabolism · 2026Article
- Article
- Management of Recurrent and Aggressive Non-Functioning Pituitary Adenomas.Journal of clinical medicine · 2025Review
- A Bridge Too Far? Towards Medical Therapy for Clinically Nonfunctioning Pituitary Tumors.International journal of molecular sciences · 2025Review
- Successful Volume Control of Invasive Pituitary Adenoma Tumor With Pasireotide: A New Horizon for a Challenging Disease.JCEM case reports · 2025Article
- Long-term survival in a patient with metastatic prolactinoma: a 12-year follow-up.Proceedings (Baylor University. Medical Center) · 2025Article
- Targeting HTR2B suppresses nonfunctioning pituitary adenoma growth and sensitizes cabergoline treatment via inhibiting Gαq/PLC/PKCγ/STAT3 axis.Neuro-oncology · 2024Article
- Clinical features of pituitary carcinoma: analysis based on a case report and literature review.Frontiers in endocrinology · 2024Review
- Update on Current Evidence for the Diagnosis and Management of Nonfunctioning Pituitary Neuroendocrine Tumors.Endocrinology and metabolism (Seoul, Korea) · 2023Review
- The Role of Aromatase Inhibitors in Male Prolactinoma.Journal of clinical medicine · 2023Review
- Targeting the Tumor Immune Microenvironment Could Become a Potential Therapeutic Modality for Aggressive Pituitary Adenoma.Brain sciences · 2023Article
- Current and Perspective Approaches to the Treatment of Prolactinomas.Acta medica Lituanic · 2023Review
- Expression and methylation status of MMR and MGMT in well-differentiated pancreatic neuroendocrine tumors and potential clinical applications.Endocrine · 2022Article
- Review
- Aggressive giant prolactinoma: a case report.Journal of medical case reports · 2022Article
- High-risk pituitary adenomas and strategies for predicting response to treatment.Hormones (Athens, Greece) · 2022Review
- Temozolomide Nonresponsiveness in Aggressive Prolactinomas and Carcinomas: Management and Outcomes.Journal of the Endocrine Society · 2022Article
- Multimodal Non-Surgical Treatments of Aggressive Pituitary Tumors.Frontiers in endocrinology · 2021Review
- A Silent Corticotroph Pituitary Carcinoma: Lessons From an Exceptional Case Report.Frontiers in endocrinology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Temozolomide (TMZ) has been shown as an effective treatment option in aggressive pituitary adenomas and carcinomas. This review analyses the published case series and demonstrates 42 % of patents show a radiological response and 27 % experience stable disease following TMZ. Prolactinomas and corticotroph tumours respond best to TMZ, showing approximately a 50 % response rate, with non-functioning tumours responding only half as frequently. Other factors that may predict the tumour's TMZ response include MGMT and MSH status, but neither is sufficiently robust to determine treatment decisions. TMZ has an accepted role in treating pituitary carcinoma and adenomas if radiation and surgery have failed to control tumour growth. To use TMZ on the basis of anticipated future aggression, as a primary therapy, or in preference to radiotherapy remains controversial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.